151 related articles for article (PubMed ID: 37355053)
1. ASCL1-mediated ferroptosis resistance enhances the progress of castration-resistant prostate cancer to neurosecretory prostate cancer.
Nie J; Zhang P; Liang C; Yu Y; Wang X
Free Radic Biol Med; 2023 Aug; 205():318-331. PubMed ID: 37355053
[TBL] [Abstract][Full Text] [Related]
2. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
DeLucia DC; Cardillo TM; Ang L; Labrecque MP; Zhang A; Hopkins JE; De Sarkar N; Coleman I; da Costa RMG; Corey E; True LD; Haffner MC; Schweizer MT; Morrissey C; Nelson PS; Lee JK
Clin Cancer Res; 2021 Feb; 27(3):759-774. PubMed ID: 33199493
[TBL] [Abstract][Full Text] [Related]
3. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
[TBL] [Abstract][Full Text] [Related]
4.
Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
[TBL] [Abstract][Full Text] [Related]
5. Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.
Zhang A; Lau NA; Wong A; Brown LG; Coleman IM; De Sarkar N; Li D; DeLucia DC; Labrecque MP; Nguyen HM; Conner JL; Dumpit RF; True LD; Lin DW; Corey E; Alumkal JJ; Nelson PS; Morrissey C; Lee JK
Cancer Res Commun; 2023 Nov; 3(11):2358-2374. PubMed ID: 37823778
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
[TBL] [Abstract][Full Text] [Related]
7. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
[No Abstract] [Full Text] [Related]
8. Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer.
Zhang H; Zhou Y; Feng Y; Hou W; Chen Y; Xing Z; Zhang Y; Wei Q; Yin Y; Guo J; Hu H
Clin Transl Med; 2024 May; 14(5):e1678. PubMed ID: 38736108
[TBL] [Abstract][Full Text] [Related]
9. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.
Flores-Morales A; Bergmann TB; Lavallee C; Batth TS; Lin D; Lerdrup M; Friis S; Bartels A; Kristensen G; Krzyzanowska A; Xue H; Fazli L; Hansen KH; Røder MA; Brasso K; Moreira JM; Bjartell A; Wang Y; Olsen JV; Collins CC; Iglesias-Gato D
Clin Cancer Res; 2019 Jan; 25(2):595-608. PubMed ID: 30274982
[TBL] [Abstract][Full Text] [Related]
10. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
[TBL] [Abstract][Full Text] [Related]
11. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
12. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer.
Yamada Y; Venkadakrishnan VB; Mizuno K; Bakht M; Ku SY; Garcia MM; Beltran H
Sci Transl Med; 2023 Nov; 15(722):eadf6732. PubMed ID: 37967200
[TBL] [Abstract][Full Text] [Related]
13. Dependence on MUC1-C in Progression of Neuroendocrine Prostate Cancer.
Kufe D
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835130
[TBL] [Abstract][Full Text] [Related]
14. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
[TBL] [Abstract][Full Text] [Related]
15. Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients.
Bhagirath D; Liston M; Akoto T; Lui B; Bensing BA; Sharma A; Saini S
Sci Rep; 2021 Apr; 11(1):8279. PubMed ID: 33859239
[TBL] [Abstract][Full Text] [Related]
16. LIN28B promotes the development of neuroendocrine prostate cancer.
Lovnicki J; Gan Y; Feng T; Li Y; Xie N; Ho CH; Lee AR; Chen X; Nappi L; Han B; Fazli L; Huang J; Gleave ME; Dong X
J Clin Invest; 2020 Oct; 130(10):5338-5348. PubMed ID: 32634132
[TBL] [Abstract][Full Text] [Related]
17. SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate cancer.
Li H; Wang L; Li Z; Geng X; Li M; Tang Q; Wu C; Lu Z
Lab Invest; 2020 Apr; 100(4):570-582. PubMed ID: 31772313
[TBL] [Abstract][Full Text] [Related]
18. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
19. N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
Yin Y; Xu L; Chang Y; Zeng T; Chen X; Wang A; Groth J; Foo WC; Liang C; Hu H; Huang J
Mol Cancer; 2019 Jan; 18(1):11. PubMed ID: 30657058
[TBL] [Abstract][Full Text] [Related]
20. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]